stockrowAmylyx Pharmaceuticals, Inc. (AMLX) vs Xeris Biopharma Holdings, Inc. (XERS)
- Amylyx Pharmaceuticals, Inc. AMLX 29.30 +6.08%
- Xeris Biopharma Holdings, Inc. XERS 15.16 +15.90%
Amylyx Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Amylyx Pharmaceuticals, Inc. is the larger, with a market value of $3.5B against $2.4B — 1.5× the size. Xeris Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 38.4% against −77.1%. Amylyx Pharmaceuticals, Inc. has the higher net margin (0.00% vs −1.76%) and the lower return on invested capital (0.00% vs 27.2%). Across the 17 metrics below, Xeris Biopharma Holdings, Inc. leads on 12 and Amylyx Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | AMLX | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 87.38% | 53.51% |
| Operating margin | 0.00% | 12.70% | 0.00% |
| Net margin | 0.00% | (1.76%) | (2.31%) |
| Free cash flow margin | 0.00% | 20.00% | 0.00% |
| Return on equity | (74.73%) | (27.11%) | (0.80%) |
| Return on assets | (66.25%) | (1.64%) | (1.67%) |
| Return on invested capital | 0.00% | 27.22% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack